Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
Background The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and i...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001089.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846171371151818752 |
|---|---|
| author | Vincenzo Montesarchio Paolo Antonio Ascierto Antonio Maria Grimaldi Marcello Curvietto Domenico Mallardo Marco Palla Chiara Iommelli Antonella Bianco Elio Manzillo Fiorentino Fraganza Cristiana Palumbo Gaetano Rea Patrizia Murino Rosanna De Rosa Luigi Atripaldi Maurizio D’Abbraccio Egidio Celentano Claudia Trojaniello Maria Grazia Vitale Samuel Lewis Million-Weaver Roberto Parrella |
| author_facet | Vincenzo Montesarchio Paolo Antonio Ascierto Antonio Maria Grimaldi Marcello Curvietto Domenico Mallardo Marco Palla Chiara Iommelli Antonella Bianco Elio Manzillo Fiorentino Fraganza Cristiana Palumbo Gaetano Rea Patrizia Murino Rosanna De Rosa Luigi Atripaldi Maurizio D’Abbraccio Egidio Celentano Claudia Trojaniello Maria Grazia Vitale Samuel Lewis Million-Weaver Roberto Parrella |
| author_sort | Vincenzo Montesarchio |
| collection | DOAJ |
| description | Background The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing.Study description In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease.Conclusions This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment. |
| format | Article |
| id | doaj-art-e73bdd141cc34cab8a9b7d641f45494b |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-e73bdd141cc34cab8a9b7d641f45494b2024-11-11T03:05:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-10-018210.1136/jitc-2020-001089Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in ItalyVincenzo Montesarchio0Paolo Antonio Ascierto1Antonio Maria Grimaldi2Marcello Curvietto3Domenico Mallardo4Marco Palla5Chiara Iommelli6Antonella Bianco7Elio Manzillo8Fiorentino Fraganza9Cristiana Palumbo10Gaetano Rea11Patrizia Murino12Rosanna De Rosa13Luigi Atripaldi14Maurizio D’Abbraccio15Egidio Celentano16Claudia Trojaniello17Maria Grazia Vitale18Samuel Lewis Million-Weaver19Roberto Parrella2016 U.O.C. Oncologia, Azienda Ospedaliera dei Colli, Monaldi Hospital, Napoli, Campania, Italy8 Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, ItalyAff1 Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori di Napoli Fondazione “G. Pascale”O.U. Melanoma Napoli ItalyAff1 Istituto Tumori di Napoli, Fondazione Pascale Italy1Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, ItalyMelanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy1 Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy1 Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy2 Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy3 Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy4 Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy4 Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy3 Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy3 Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy4 Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy2 Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy6 Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy1Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy1Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy7 Independent Investigator, Madison, Wisconsin, USA2 Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, ItalyBackground The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and interleukin 6 (IL-6). Initial reports from the outbreak in Italy, China and the USA have provided anecdotal evidence of improved outcomes with the administration of anti-IL-6 agents, and large-scale trials evaluating these therapies are ongoing.Study description In this retrospective case series, clinical outcomes and correlates of response to treatment with the IL-6 receptor antagonist sarilumab are described for 15 patients with COVID-19 from a single institution in Southern Italy. Among 10 patients whose symptoms improved after sarilumab treatment, rapid decreases in CRP levels corresponded with clinical improvement. Lower levels of IL-6 at baseline as well as lower neutrophil to lymphocyte ratio as compared with patients whose COVID-19 did not improve with treatment were associated with sarilumab-responsive disease.Conclusions This observation may reflect a possible clinical benefit regarding early intervention with IL-6-modulatory therapies for COVID-19 and that CRP could be a potential biomarker of response to treatment.https://jitc.bmj.com/content/8/2/e001089.full |
| spellingShingle | Vincenzo Montesarchio Paolo Antonio Ascierto Antonio Maria Grimaldi Marcello Curvietto Domenico Mallardo Marco Palla Chiara Iommelli Antonella Bianco Elio Manzillo Fiorentino Fraganza Cristiana Palumbo Gaetano Rea Patrizia Murino Rosanna De Rosa Luigi Atripaldi Maurizio D’Abbraccio Egidio Celentano Claudia Trojaniello Maria Grazia Vitale Samuel Lewis Million-Weaver Roberto Parrella Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy Journal for ImmunoTherapy of Cancer |
| title | Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy |
| title_full | Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy |
| title_fullStr | Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy |
| title_full_unstemmed | Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy |
| title_short | Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy |
| title_sort | outcomes and biomarker analyses among patients with covid 19 treated with interleukin 6 il 6 receptor antagonist sarilumab at a single institution in italy |
| url | https://jitc.bmj.com/content/8/2/e001089.full |
| work_keys_str_mv | AT vincenzomontesarchio outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT paoloantonioascierto outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT antoniomariagrimaldi outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT marcellocurvietto outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT domenicomallardo outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT marcopalla outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT chiaraiommelli outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT antonellabianco outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT eliomanzillo outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT fiorentinofraganza outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT cristianapalumbo outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT gaetanorea outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT patriziamurino outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT rosannaderosa outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT luigiatripaldi outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT mauriziodabbraccio outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT egidiocelentano outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT claudiatrojaniello outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT mariagraziavitale outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT samuellewismillionweaver outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly AT robertoparrella outcomesandbiomarkeranalysesamongpatientswithcovid19treatedwithinterleukin6il6receptorantagonistsarilumabatasingleinstitutioninitaly |